fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study
No safety signals were identified, and the incidence of local AEs declined over the duration of fSCIG 10% treatment. This study supports fSCIG 10% long-term safety in children with PIDs. TRIAL REGISTRATION NUMBER (CLINICALTRIALS.GOV): NCT03116347.
Authors
- Marion Roderick (ORCID: https://orcid.org/0000-0002-8481-6300)
- Stephen Jolles (ORCID: https://orcid.org/0000-0002-7394-6804)
- Miloš Jeseňák (ORCID: https://orcid.org/0000-0001-7976-2523)
- Gergely Kriván (ORCID: https://orcid.org/0000-0003-4853-4354)
- Katharina Fielhauer
- Charles Atisso
- Leman Yel (ORCID: https://orcid.org/0000-0001-8357-3186)
- Nicholas Brodszki (ORCID: https://orcid.org/0000-0001-5355-7919)
- Peter Čižnár (ORCID: https://orcid.org/0000-0003-0566-1644)
- Shumyla Saeed-Khawaja
- Helen Schneiderova
- Barbara McCoy
Institutions
- University of California, Irvine (US)
- Masaryk University (CZ)
- University Hospital of Wales (GB)
- Bristol Royal Hospital for Children (GB)
- National Institute of Oncology (HU)
- UC Irvine Health (US)
- Skåne University Hospital (SE)
- Takeda (United States) (US)
- Irvine University (US)
- Takeda (Austria) (AT)
- Comenius University Bratislava (SK)
Publication Details
- Journal
- Allergy Asthma and Clinical Immunology
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1186/s13223-024-00904-9
- Citations
- 2
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.48
Funders
- Baxalta
- Takeda Pharmaceuticals International